Published online before print February 21, 2005, doi: 10.1161/01.CIR.0000156466.02908.ED
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2005;111:1012-1018.)
© 2005 American Heart Association, Inc.
Hypertension |
Aliskiren, a Novel Orally Effective Renin Inhibitor, Provides Dose-Dependent Antihypertensive Efficacy and Placebo-Like Tolerability in Hypertensive Patients
From The Western Pennsylvania Hospital, Pittsburgh, PA (A.H.G.); University of Erlangen-Nürnberg, Erlangen, Germany (R.E.S.); A.Z. Jan Palfijn-Gallifort, Merksem, Belgium (R.L.L.); Department of Internal Medicine, CHUV, Lausanne, Switzerland (J.N.); and Cardiovascular and Metabolism Clinical Research, Novartis, East Hanover, NJ (Y.C., M.P.B.).
Correspondence to Martin P. Bedigian, MD, Cardiovascular and Metabolism Clinical Research, Novartis, One Health Plaza, East Hanover, NJ 07936. E-mail martin.bedigian{at}pharma.novartis.com
Received June 4, 2004; revision received October 21, 2004; accepted December 13, 2004.
Background— Stopping the detrimental effects of the renin-angiotensin system at the most upstream point of the cascade offers theoretical advantages for cardiovascular protection. This study compares the antihypertensive efficacy and safety of the novel oral renin inhibitor aliskiren with placebo and an active comparator.
Methods and Results— The study was a randomized, multicenter, double-blind, placebo-controlled, active-comparator 8-week trial in patients with mild-to-moderate hypertension (mean sitting diastolic blood pressure [DBP] 
95 and <110 mm Hg). After a 2-week, single-blind placebo run-in, 652 patients were randomized to receive double-blind treatment with once-daily oral doses of aliskiren (150, 300, or 600 mg), irbesartan 150 mg, or placebo. Aliskiren 150, 300, and 600 mg effectively lowered both trough mean sitting DBP and systolic blood pressure (SBP) (P<0.001 versus placebo for both variables). The least-squares mean reductions in trough DBP were 9.3±0.8, 11.8±0.8, and 11.5±0.8 mm Hg, respectively, versus 6.3±0.8 mm Hg for placebo, and the least-squares mean reductions in trough SBP were 11.4±1.3, 15.8±1.2, and 15.7±1.2 mm Hg, respectively, versus 5.3±1.2 mm Hg for placebo. The antihypertensive effect of aliskiren 150 mg was comparable to that of irbesartan 150 mg (8.9±0.7 and 12.5±1.2 mm Hg, least-squares reduction in mean sitting DBP and SBP, respectively, for irbesartan). Aliskiren 300 and 600 mg lowered mean sitting DBP significantly more than irbesartan 150 mg (P<0.05). Aliskiren showed safety and tolerability comparable to those of placebo and irbesartan; the incidence of adverse events and number of patients discontinuing therapy were similar in all groups.
Conclusions— Once-daily oral treatment with aliskiren lowers blood pressure effectively, with a safety and tolerability profile comparable to that of irbesartan and placebo, in patients with mild-to-moderate hypertension. Aliskiren 150 mg is as effective as irbesartan 150 mg in lowering blood pressure.
Key Words: angiotensin • blood pressure • hypertension • renin
Related Article:
Circulation 2005 111: 955.
This article has been cited by other articles:
 |
|
 |
|
  J. Ino, C. Kojima, M. Osaka, K. Nitta, and M. Yoshida Dynamic Observation of Mechanically-Injured Mouse Femoral Artery Reveals an Antiinflammatory Effect of Renin Inhibitor Arterioscler Thromb Vasc Biol, November 1, 2009; 29(11): 1858 - 1863. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Andersen, M. H Weinberger, C. M Constance, M. A Ali, J. Jin, M. F Prescott, and D. L Keefe Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension Journal of Renin-Angiotensin-Aldosterone System, September 1, 2009; 10(3): 157 - 167. [Abstract] [PDF]
|
|
|
|
|
|
P. S Sever, A. H Gradman, and M. Azizi Managing cardiovascular and renal risk: the potential of direct renin inhibition Journal of Renin-Angiotensin-Aldosterone System, June 1, 2009; 10(2): 65 - 76. [Abstract] [PDF]
|
|
|
|
 |
|
 H.-H. Parving, B. M. Brenner, John. J. V. McMurray, D. de Zeeuw, S. M. Haffner, S. D. Solomon, N. Chaturvedi, M. Ghadanfar, N. Weissbach, Z. Xiang, et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design Nephrol. Dial. Transplant., May 1, 2009; 24(5): 1663 - 1671. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Solomon, E. Appelbaum, W. J. Manning, A. Verma, T. Berglund, V. Lukashevich, C. Cherif Papst, B. A. Smith, B. Dahlof, and for the Aliskiren in Left Ventricular Hypertrophy Effect of the Direct Renin Inhibitor Aliskiren, the Angiotensin Receptor Blocker Losartan, or Both on Left Ventricular Mass in Patients With Hypertension and Left Ventricular Hypertrophy Circulation, February 3, 2009; 119(4): 530 - 537. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E. Schmieder, T. Philipp, J. Guerediaga, M. Gorostidi, B. Smith, N. Weissbach, M. Maboudian, J. Botha, and H. van Ingen Long-Term Antihypertensive Efficacy and Safety of the Oral Direct Renin Inhibitor Aliskiren: A 12-Month Randomized, Double-Blind Comparator Trial With Hydrochlorothiazide Circulation, January 27, 2009; 119(3): 417 - 425. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Vaidyanathan, G. Camenisch, H. Schuetz, C. Reynolds, C.-M. Yeh, M.-N. Bizot, H. A. Dieterich, D. Howard, and W. P. Dole Pharmacokinetics of the Oral Direct Renin Inhibitor Aliskiren in Combination With Digoxin, Atorvastatin, and Ketoconazole in Healthy Subjects: The Role of P-Glycoprotein in the Disposition of Aliskiren J. Clin. Pharmacol., November 1, 2008; 48(11): 1323 - 1338. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 {blacktriangledown}Aliskiren for hypertension in adults DTB, October 1, 2008; 46(10): 73 - 76. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Dietz, R. Dechend, C.-M. Yu, M. Bheda, J. Ford, M. F. Prescott, and D. L. Keefe Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension1 Journal of Renin-Angiotensin-Aldosterone System, September 1, 2008; 9(3): 163 - 175. [Abstract] [PDF]
|
|
|
|
 |
|
 T. Imanishi, H. Tsujioka, H. Ikejima, A. Kuroi, S. Takarada, H. Kitabata, T. Tanimoto, Y. Muragaki, S. Mochizuki, M. Goto, et al. Renin Inhibitor Aliskiren Improves Impaired Nitric Oxide Bioavailability and Protects Against Atherosclerotic Changes Hypertension, September 1, 2008; 52(3): 563 - 572. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Brown Aliskiren Circulation, August 12, 2008; 118(7): 773 - 784. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. K. Daugherty Aliskiren Am. J. Health Syst. Pharm., July 15, 2008; 65(14): 1323 - 1332. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ayalasomayajula, C.-M. Yeh, S. Vaidyanathan, B. Flannery, H. A. Dieterich, D. Howard, M. P. Bedigian, and W. P. Dole Effects of Aliskiren, a Direct Renin Inhibitor, on Cardiac Repolarization and Conduction in Healthy Subjects J. Clin. Pharmacol., July 1, 2008; 48(7): 799 - 811. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Feldman, L. Jin, H. Xuan, A. Contrepas, Y. Zhou, R. L. Webb, D. N. Mueller, S. Feldt, F. Cumin, W. Maniara, et al. Effects of Aliskiren on Blood Pressure, Albuminuria, and (Pro)Renin Receptor Expression in Diabetic TG(mRen-2)27 Rats Hypertension, July 1, 2008; 52(1): 130 - 136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-H. Parving, F. Persson, J. B. Lewis, E. J. Lewis, N. K. Hollenberg, and the AVOID Study Investigators Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy N. Engl. J. Med., June 5, 2008; 358(23): 2433 - 2446. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Williams The Year in Hypertension J. Am. Coll. Cardiol., May 6, 2008; 51(18): 1803 - 1817. [Full Text] [PDF]
|
|
|
|
|
|
S. Feldt, W. W. Batenburg, I. Mazak, U. Maschke, M. Wellner, H. Kvakan, R. Dechend, A. Fiebeler, C. Burckle, A. Contrepas, et al. Prorenin and Renin-Induced Extracellular Signal-Regulated Kinase 1/2 Activation in Monocytes Is Not Blocked by Aliskiren or the Handle-Region Peptide Hypertension, March 1, 2008; 51(3): 682 - 688. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. H. Gradman and R. Kad Renin inhibition in hypertension. J. Am. Coll. Cardiol., February 5, 2008; 51(5): 519 - 528. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Campbell Interpretation of Plasma Renin Concentration in Patients Receiving Aliskiren Therapy Hypertension, January 1, 2008; 51(1): 15 - 18. [Full Text] [PDF]
|
|
|
|
|
|
Y. Uresin, A. A Taylor, C. Kilo, D. Tschope, M. Santonastaso, G. Ibram, Hui Fang, and A. Satlin Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension Journal of Renin-Angiotensin-Aldosterone System, December 1, 2007; 8(4): 190 - 200. [Abstract] [PDF]
|
|
|
|
 |
|
 Y. Bukhtiyarov, M. Zecher, R. Panemangalore, Z. Wu, J. G. Bruno, J. Yuan, Z. Xu, L. W. Dillard, G. M. McGeehan, R. K. Harrison, et al. Cloning, Characterization and Site-Directed Mutagenesis of Canine Renin J. Biochem., December 1, 2007; 142(6): 671 - 680. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Seed, R. Gardner, J. McMurray, C. Hillier, D. Murdoch, R. MacFadyen, A. Bobillier, J. Mann, and T. McDonagh Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure Eur J Heart Fail, November 1, 2007; 9(11): 1120 - 1127. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Segall, A. Covic, and D. J. A. Goldsmith Direct renin inhibitors: the dawn of a new era, or just a variation on a theme? Nephrol. Dial. Transplant., September 1, 2007; 22(9): 2435 - 2439. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Kobori, M. Nangaku, L. G. Navar, and A. Nishiyama The Intrarenal Renin-Angiotensin System: From Physiology to the Pathobiology of Hypertension and Kidney Disease Pharmacol. Rev., September 1, 2007; 59(3): 251 - 287. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Azizi, J. Menard, A. Bissery, T.-T. Guyene, and A. Bura-Riviere Hormonal and Hemodynamic Effects of Aliskiren and Valsartan and Their Combination in Sodium-Replete Normotensive Individuals Clin. J. Am. Soc. Nephrol., September 1, 2007; 2(5): 947 - 955. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Waldmeier, U. Glaenzel, B. Wirz, L. Oberer, D. Schmid, M. Seiberling, J. Valencia, G.-J. Riviere, P. End, and S. Vaidyanathan Absorption, Distribution, Metabolism, and Elimination of the Direct Renin Inhibitor Aliskiren in Healthy Volunteers Drug Metab. Dispos., August 1, 2007; 35(8): 1418 - 1428. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Authors/Task Force Members:, G. Mancia, G. De Backer, A. Dominiczak, R. Cifkova, R. Fagard, G. Germano, G. Grassi, A. M. Heagerty, S. E. Kjeldsen, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Eur. Heart J., June 11, 2007; (2007) ehm236v1. [Full Text] [PDF]
|
|
|
|
|
|
J. Jordan, S. Engeli, S. W. Boye, S. Le Breton, and D. L. Keefe Direct Renin Inhibition With Aliskiren in Obese Patients With Arterial Hypertension Hypertension, May 1, 2007; 49(5): 1047 - 1055. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Vaidyanathan, C. Reynolds, C.-M. Yeh, M.-N. Bizot, H. A. Dieterich, D. Howard, and W. P. Dole Pharmacokinetics, Safety, and Tolerability of the Novel Oral Direct Renin Inhibitor Aliskiren in Elderly Healthy Subjects J. Clin. Pharmacol., April 1, 2007; 47(4): 453 - 460. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Newton-Cheh, C.-Y. Guo, P. Gona, M. G. Larson, E. J. Benjamin, T. J. Wang, S. Kathiresan, C. J. O'Donnell, S. L. Musone, A. L. Camargo, et al. Clinical and Genetic Correlates of Aldosterone-to-Renin Ratio and Relations to Blood Pressure in a Community Sample Hypertension, April 1, 2007; 49(4): 846 - 856. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B.-H. Oh, J. Mitchell, J. R. Herron, J. Chung, M. Khan, and D. L. Keefe Aliskiren, an Oral Renin Inhibitor, Provides Dose-Dependent Efficacy and Sustained 24-Hour Blood Pressure Control in Patients With Hypertension J. Am. Coll. Cardiol., March 20, 2007; 49(11): 1157 - 1163. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. W Van Tassell and M. A Munger Aliskiren for Renin Inhibition: A New Class of Antihypertensives Ann. Pharmacother., March 1, 2007; 41(3): 456 - 464. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. O'Brien, J. Barton, J. Nussberger, D. Mulcahy, C. Jensen, P. Dicker, and A. Stanton Aliskiren Reduces Blood Pressure and Suppresses Plasma Renin Activity in Combination With a Thiazide Diuretic, an Angiotensin-Converting Enzyme Inhibitor, or an Angiotensin Receptor Blocker Hypertension, February 1, 2007; 49(2): 276 - 284. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A Sica The pharmacology of agents that interfere with renin-angiotensin system activity Journal of Renin-Angiotensin-Aldosterone System, December 1, 2006; 7(4): 247 - 250. [PDF]
|
|
|
|
|
|
L. Ruilope Introduction Journal of Renin-Angiotensin-Aldosterone System, June 1, 2006; 7(2_suppl): S1 - S2. [PDF]
|
|
|
|
|
|
R. E Schmieder Aliskiren: a clinical profile Journal of Renin-Angiotensin-Aldosterone System, June 1, 2006; 7(2_suppl): S16 - S20. [Abstract] [PDF]
|
|
|
|
|
|
D. N. Muller and F. C. Luft Direct Renin Inhibition with Aliskiren in Hypertension and Target Organ Damage Clin. J. Am. Soc. Nephrol., March 1, 2006; 1(2): 221 - 228. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.H. J. Danser and J. Deinum Renin, Prorenin and the Putative (Pro)renin Receptor Hypertension, November 1, 2005; 46(5): 1069 - 1076. [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Mallare, A. H. Karabell, P. Velasquez-Mieyer, S. R.S. Stender, and M. L. Christensen Current and Future Treatment of Metabolic Syndrome and Type 2 Diabetes in Children and Adolescents Diabetes Spectr, October 1, 2005; 18(4): 220 - 228. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Kelly, J. L. Wilkinson-Berka, and R. E. Gilbert Renin Inhibition: New Potential for an Old Therapeutic Target Hypertension, September 1, 2005; 46(3): 471 - 472. [Full Text] [PDF]
|
|